Impact of pancreas transplantation on diabetic secondary complications and quality of life R. Landgraf Review Pages: 1415 - 1424
Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture A. PandolfiL. IacovielloA. Consoli Originals Pages: 1425 - 1431
Comparison of the effects of insulin, PDGF, interleukin-6, and interferon-g on glucose transport in 3T3-L1 cells: lack of cross-talk between tyrosine kinase receptors and JAK/STAT pathways C. HuppertzC. SchwartzH.-G. Joost Pages: 1432 - 1439
Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats P. OdettiN. TraversoU. M. Marinari Pages: 1440 - 1447
Cytokine gene expression in the BB rat pancreas: natural course and impact of bacterial vaccines H. KolbU. Wörz-PagenstertF. W. Scott Pages: 1448 - 1454
GGAAAT motifs play a major role in transcriptional activity of the human insulin gene in a pancreatic islet beta-cell line MIN6 A. TomonariK. YoshimotoM. Itakura Pages: 1462 - 1468
Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control J. L. Sánchez-QuesadaA. PérezA. de Leiva Pages: 1469 - 1476
Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects T. UtriainenS. MäkimattilaH. Yki-Järvinen Pages: 1477 - 1482
Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up P. ReichardM. PihlJ. Sule Pages: 1483 - 1488
Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children S. CaprioM. BronsonW. V. Tamborlane Pages: 1489 - 1497
Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM H. Hanaire-BroutinB. Sallerin-CauteJ. P. Tauber Pages: 1498 - 1504
UKPDS 19: Heterogeneity in NIDDM: separate contributions of IRS-1 and b3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations Y. ZhangN. WatR. C. Turner Pages: 1505 - 1511
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome L. J. McCormackD. K. NagiP. J. Grant Pages: 1512 - 1518
Altered properties of the fibrin gel structure in patients with IDDM G. JörneskogN. EgbergM. Blombäck Pages: 1519 - 1523
Lens autofluorescence is increased in newly diagnosed patients with NIDDM P. Koefoed TheilT. HansenH. Lund-Andersen Rapid communication Pages: 1524 - 1527
The causes of obesity: advances in molecular biology but stagnation on the genetic front C. Bouchard Pages: 1532 - 1533
Improving prognosis in NIDDM patients Carl Erik MogensenRobert TurnerRudy Bilous Preface Pages: 1539 - 1539
Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project E. StandlB. BalletshoferR. Holle Original studies Pages: 1540 - 1545
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM M. A. NauckD. WollschlägerB. Willms Pages: 1546 - 1553
Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control Hypertension in Diabetes Study Group* I. StrattonS. ManleyR. Turner Report prepared for publication by: I. M. Stratton, S. E. Manley, R. R. Holman, R. C. Turner--> Pages: 1554 - 1561
Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans P. J. BijlstraJ. A. C. J. den ArendP. Smits Pages: 1562 - 1568
Patterns of renal injury in NIDDM patients with microalbuminuria P. FiorettoM. MauerR. Nosadini Pages: 1569 - 1576
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up M. HanefeldS. FischerThe DIS Group Pages: 1577 - 1583
Glomerular hyperfiltration in microalbuminuric NIDDM patients P. VedelJ. ObelH.-H. Parving Pages: 1584 - 1589
Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy H.-H. ParvingF. S. NielsenP. Rossing Pages: 1590 - 1597
Birth weight and cardiovascular risk factors in an epidemiological study E. VestboE. M. DamsgaardC. E. Mogensen Pages: 1598 - 1602
Relationship between diastolic hypertension and myocardial morphology and function in elderly males with diabetes mellitus L. LindC. BerneH. Lithell Reports Pages: 1603 - 1606
Major lower limb amputation in diabetic patients: development during 1982 to 1993 B. EbskovL. Ebskov Pages: 1607 - 1610
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria C. SchnackW. HoffmannG. Schernthaner Pages: 1611 - 1616
Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment B. RosenkranzV. ProfozicV. Malerczyk Pages: 1617 - 1624
Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study T. BertaniV. GambaraG. Remuzzi Pages: 1625 - 1628
NIDDM: a rapid progressive disease Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment K. I. BirkelandU. RishaugS. Vaaler Pages: 1629 - 1633
Low birth weight – is it associated with few and small glomeruli in normal subjects and NIDDM patients? J. R. NyengaardT. F. BendtsenC. E. Mogensen Pages: 1634 - 1637
How often is NIDDM complicated with non-diabetic renal disease? An analysis of renal biopsies and the literature S. OlsenC. E. Mogensen Pages: 1638 - 1645
Appropriate Blood Pressure Control in NIDDM (ABCD) Trial R. W. SchrierR. O. EstacioB. Jeffers Clinical trial design Pages: 1646 - 1654
The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization G. Steiner Pages: 1655 - 1661
End-stage renal disease in NIDDM: a consequence of microangiopathy alone? A. E. G. RaineR. W. Bilous Pages: 1673 - 1675
